Bloomberg was the first to report the deal. AtaiBeckley is one of several companies poised to usher in this new era of psychedelics .
GH001 Draws Comparisons With AtaiBeckley’s Lead Drug Candidate
GH Research’s lead drug, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach, similar to AtaiBeckley’s lead asset, BPL-003 (mebufotenin benzoate), administered intranasally for treatment-resistant depression.
Prior Data Supports Treatment-Resistant Depression Program
In March 2026, the results of the Phase 2b trial in TRD (GH001-TRD-201) were published in JAMA Psychiatry .
A post-hoc analysis reported alongside the publication demonstrated efficacy independent of the number of prior antidepressant treatment failures, with Day 8 remission rates of 53.9%-63.6% across subgroups.
In May, GH Research said it completed enrolment in a Phase 1 pharmacology trial in the U.K., evaluating a proprietary aerosol delivery device for the administration of GH001 in healthy volunteers (GH001-HV-106).
The company selected the doses for the global Phase 3 pivotal program based on the results from this trial for treatment-resistant depression.
In January, the U.S. Food and Drug Administration (FDA) lifted the clinical hold on GH Research’s Investigational New Drug Application (IND) for GH001 after the FDA placed a clinical hold in September 2023 due to insufficient information to assess risks to human subjects.
Shorter Treatment Duration For BPL-003
Bloomberg’s report on Thursday noted that BPL-003’s shorter treatment duration is a key advantage.
Its psychedelic effects last about one to two hours, compared with some experimental therapies, including one from Compass Pathways Plc (NASDAQ: CMPS ), that may require patient monitoring for up to eight hours.
Price Action: GH Research shares were up 11.40% at $29.99, and Definium Therapeutics shares were down 1.31% at $45.06 at the time of publication on Thursday, according to Benzinga Pro data .
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Trading Ideas Movers News General Biotech Top Stories Health Care Psychedelics why it's moving